Trials / Unknown
UnknownNCT03105310
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Aga Khan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry, that include two hydrophobes and one hydrogen bond acceptor. The aim of the study io evaluate the utility of Ezetimibe in combination with pegylated interferon in patients with chronic HDV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated interferon alfa | Pegylated interferon alfa |
| DRUG | Ezetimibe | Ezetimibe |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-12-01
- Completion
- 2017-06-01
- First posted
- 2017-04-07
- Last updated
- 2017-04-07
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03105310. Inclusion in this directory is not an endorsement.